Second generation oral hypoglycemic agent. Acts via ATP-dependent K+ channel (Kir6, KATP) block1. Inhibits Kir6 currents in the pancreas, causing an increase in intracellular Ca2+ and insulin secretion. Also inhibits recombinant CFTR Cl- channels with an
* VAT and and shipping costs not included. Errors and price changes excepted